Boston Scientific's (BSX) Farapulse and Watchman products are expected to drive upside following the discontinuation of global sales of the Acurate transcatheter aortic valve replacements, Needham said in a note Wednesday.
The company announced earlier Wednesday it will discontinue sales of Acurate neo2 and Acurate Prime as well as halt efforts to secure US Food and Drug Administration and other market approvals after recent discussions with regulators led to increased clinical and regulatory requirements for Acurate products.
Needham said Boston Scientific expects to offset the impact of Acurate's shelving with other growth drivers such as Farapulse and Watchman as the company reiterated its outlook for Q2 and 2025.
"We view any weakness in BSX shares today as a buying opportunity given our expectation that Farapulse and Watchman continue to drive upside to consensus estimates," Needham said. "We expect the Champion trial results to be a major catalyst in H1 2026."
Needham has a buy rating on Boston Scientific, with a $115 price target.
Price: 104.73, Change: -1.45, Percent Change: -1.36
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。